692 related articles for article (PubMed ID: 29080691)
1. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis.
Xu Y; Zhang Y; Wang X; Kang J; Liu X
BMC Cancer; 2019 Feb; 19(1):168. PubMed ID: 30795756
[TBL] [Abstract][Full Text] [Related]
3. Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2018 May; 480():166-172. PubMed ID: 29462592
[TBL] [Abstract][Full Text] [Related]
4. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Liu Y; Zhou L; Chen Y; Liao B; Ye D; Wang K; Li H
BMC Urol; 2019 Jun; 19(1):49. PubMed ID: 31174518
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
[TBL] [Abstract][Full Text] [Related]
6. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Yasuda Y; Saito K; Yuasa T; Uehara S; Kawamura N; Yokoyama M; Ishioka J; Matsuoka Y; Yamamoto S; Okuno T; Yonese J; Kihara K; Fujii Y
Int J Clin Oncol; 2017 Dec; 22(6):1081-1086. PubMed ID: 28733795
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and clinicopathological value of PBRM1 expression in renal cell carcinoma.
Wang Z; Peng S; Guo L; Xie H; Wang A; Shang Z; Niu Y
Clin Chim Acta; 2018 Nov; 486():9-17. PubMed ID: 30006290
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Shen J; Chen Z; Zhuang Q; Fan M; Ding T; Lu H; He X
PLoS One; 2016; 11(11):e0166482. PubMed ID: 27861542
[TBL] [Abstract][Full Text] [Related]
10. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.
Na N; Yao J; Cheng C; Huang Z; Hong L; Li H; Qiu J
Oncotarget; 2016 Jul; 7(28):44039-44046. PubMed ID: 27270655
[TBL] [Abstract][Full Text] [Related]
13. Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.
Dalpiaz O; Luef T; Seles M; Stotz M; Stojakovic T; Pummer K; Zigeuner R; Hutterer GC; Pichler M
Br J Cancer; 2017 Jan; 116(1):85-90. PubMed ID: 27907929
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis.
Semeniuk-Wojtaś A; Lubas A; Stec R; Syryło T; Niemczyk S; Szczylik C
Clin Genitourin Cancer; 2018 Jun; 16(3):e685-e693. PubMed ID: 29454639
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis.
Hu Q; Gou Y; Sun C; Ding W; Xu K; Gu B; Xia G; Ding Q
Urol Oncol; 2014 Jan; 32(1):50.e1-8. PubMed ID: 24239465
[TBL] [Abstract][Full Text] [Related]
17. Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Zhou X; Fu G; Zu X; Xu Z; Li HT; D'souza A; Tulpule V; Quinn DI; Bhowmick NA; Weisenberger DJ; Liang G; Chen J
Urol Oncol; 2022 Jan; 40(1):12.e13-12.e22. PubMed ID: 34454823
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Kang M; Yu J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
Int J Urol; 2018 Jun; 25(6):596-603. PubMed ID: 29756394
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
Dai J; Tang K; Xiao W; Yu G; Zeng J; Li W; Zhang YQ; Xu H; Chen ZQ; Ye ZQ
Asian Pac J Cancer Prev; 2014; 15(8):3369-75. PubMed ID: 24870724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
